Clinical Report: Docs Flag Risks, Demand Standards for Skin Apps
Overview
A study from the Netherlands reveals physician hesitance towards AI-based skin cancer assessment apps due to risks of misdiagnosis and digital exclusion. Physicians express concerns regarding the accuracy of these apps, which could lead to misdiagnoses and inequitable access for vulnerable populations.
Background
The integration of artificial intelligence in healthcare, particularly for skin cancer assessment, presents both opportunities and challenges. Physicians express concerns regarding the accuracy of these apps, which could lead to misdiagnoses and inequitable access for vulnerable populations.
Data Highlights
No numerical data was provided in the source material.
Key Findings
- Physicians identified incorrect diagnosis as the most serious risk associated with skin cancer apps.
- Concerns were raised about digital exclusion, particularly for patients with lower digital literacy or darker skin tones.
- Participants emphasized the need for independent accuracy testing of apps using representative populations.
- Integration of apps into clinical practice must be seamless, with clear communication and privacy protections.
- Liability issues were highlighted, especially regarding independent use of apps by patients.
- Physicians agreed that skin cancer apps could be valuable tools if they are accurate, equitable, and responsibly integrated.
Clinical Implications
Healthcare professionals should remain cautious about endorsing AI-based skin cancer assessment apps until they meet established criteria for accuracy and equity.
Conclusion
Physicians remain cautious about AI skin cancer apps due to concerns about misdiagnosis and equitable access.
Related Resources & Content
- Lugtenberg M, et al., BMC, 2023 -- Docs Flag Risks, Demand Standards for Skin Apps
- npj Digital Medicine — Improving dataset transparency in dermatologic Artificial Intelligence using a dataset nutrition label
- Drug Safety — Guidelines for Utilizing Mobile Applications in Gathering and Sharing Safety Data on Pharmaceutical Products: Insights from IMI WEB-RADR
- Archives of Toxicology (Springer) — ChemSkin DB 2.0: a comprehensive reference chemical database for skin corrosion and irritation
- JAMA Dermatology — Consumer Understanding of Skin Concerns With an AI-Powered Informational Tool
- Improving dataset transparency in dermatologic Artificial Intelligence using a dataset nutrition label
- Guidelines for Utilizing Mobile Applications in Gathering and Sharing Safety Data on Pharmaceutical Products: Insights from IMI WEB-RADR
- Consumer Understanding of Skin Concerns With an AI-Powered Informational Tool
- Prospective Evidence on Artificial Intelligence−Assisted Melanoma Diagnostics: A Systematic Review and Meta-Analysis
- Guidances with Digital Health Content | FDA
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
